A cross-border Life Sciences team advised Lauxera Capital Partners on their investment in LUMICKS as part of a $93 million Series D Financing. LUMICKS is a leading life science company that develops equipment for dynamic single-molecule and cell avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), LUMICKS tools facilitate the understanding of life to the smallest detail.
The funding round was led by new investors Lauxera Capital Partners and Farallon Capital Management, along with Softbank Group, funds and accounts advised by T. Rowe Price Associates, Inc., Parian Global Management, Pura Vida Investments, and Irving Investors.
Lauxera Capital Partners is an independent, global investment firm focused on HealthTech growth companies. Founded in 2020 by a combined group of company builders and career healthcare investors, Lauxera's team is based in Paris and San Francisco in order to serve as a bridge between healthcare innovations born in the EU and global customers and capital markets. Lauxera invests in commercial-stage, EU HealthTech businesses poised to scale into market-leading category champions.
The deal team was led by Bill Schnoor and Sophie McGrath.
For additional details on the investment, please read the press release.